Will IMUX stock price drop/rise/fall?
The Immunic stock price is 9.560 USD today. Will IMUX stock price drop / fall? Yes. The Immunic stock price may drop from 9.560 USD to 0.000003 USD . The change will be -100.000 %. Will IMUX stock price grow / rise / go up?
Will IMUX outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about Immunic and other stocks. Vote “Outperform” if you believe IMUX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMUX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Are long-term investors shrugging off the extreme drops in digital coins?
Still, long-term investors are shrugging off the extreme drops in the a value of digital coins and the breakdown of the exchanges that make them available to investors.
Is immunic (im) a good stock to buy now?
The company is headquartered in New York, NY. Immunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $49.25, Immunic has a forecasted upside of 371.3% from its current price of $10.45.
Is Imux a good stock to buy?
Out of 3 analysts, 1 (33.33%) are recommending IMUX as a Strong Buy, 2 (66.67%) are recommending IMUX as a Buy, 0 (0%) are recommending IMUX as a Hold, 0 (0%) are recommending IMUX as a Sell, and 0 (0%) are recommending IMUX as a Strong Sell.
Will Imux stock go up?
The 6 analysts offering 12-month price forecasts for Immunic Inc have a median target of 56.00, with a high estimate of 64.00 and a low estimate of 39.00. The median estimate represents a +1,683.44% increase from the last price of 3.14.
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is Immunic (IMUX) Stock Outpacing Its Medical Peers This Year?
Here is how Immunic (IMUX) and Owens & Minor (OMI) have performed compared to their sector so far this year.
What is the IMUX?
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), today announced the signing of an agreement under which Immunic will settle its remaining obligation of a 4.4% royalty on net sales of selective oral DHODH inhibitor, IMU-838, for $17.25 million. The transaction will be payable 50% in cash and 50% in shares of Immunic's common stock.
What is IMUX in medicine?
(Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for the phase 3 ENSURE program of lead asset IMU-838, the company's selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS). In addition, the FDA also cl
How much does Immunic raise?
Immunic aims to raise gross proceeds of around $45 million by selling 4.5 million shares of common stock at $10 apiece in an underwritten public offering. The underwriting syndicate, led by Piper Sandler (NYSE: PIPR), has been granted a 30-day option to buy up to an extra 675,000 shares among themselves.
About Immunic
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis.
Immunic (NASDAQ:IMUX) Frequently Asked Questions
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Immunic stock. View analyst ratings for Immunic or view top-rated stocks.